Amerio PierLuigi, Capizzi Rodolfo, Milani Massimo
Clinica Dermatologica, Policlinico Universitario, Agostino Gemelli, Rome, Italy.
Eur J Dermatol. 2003 Jan-Feb;13(1):69-71.
We compared in a prospective, randomised, investigator-blinded trial, the efficacy and tolerability of a new synergised-pyrethrins thermo-labile foam (F) formulation with permethrin 5 % cream (P) in 40 patients with scabies. Clinical evolution of scabetic lesions (Clinical grading = CG) and itching intensity (IS) were assessed, using a 5-point semi-quantitative score, at baseline, at week 2 and 4. F and P were equally effective in the clinical resolution of scabetic lesions. As compared to baseline, P reduced CG and IS from 3.4 0.7 and 3.1 0.4 to 0.2 0.6 and 1.4 1, at week 2, and to 0.0 0.0 and 0.1 0.3 at week 4, respectively (P < 0.001). F reduced CG and IS from 3.3 0.5 and 3.2 0.4 to 0.05 0.2 and 0.4 0.6 (week 2) and to 0.0 0.0 and 0.0 0.0 (week 4), respectively (P < 0.0001). As compared to P group, the IS in F group, at week 2, was significantly lower (0.4 0.6 vs. 1.4 1.1) (P < 0.0013). This foam formulation was at least as effective as permethrin 5 % cream in the treatment of scabies. In comparison with permethrin the foam induced a more rapid and complete resolution of itching.
在一项前瞻性、随机、研究者盲法试验中,我们比较了一种新型增效除虫菊酯热不稳定泡沫(F)制剂与5%氯菊酯乳膏(P)对40例疥疮患者的疗效和耐受性。在基线、第2周和第4周,使用5分半定量评分评估疥疮皮损的临床演变(临床分级=CG)和瘙痒强度(IS)。F和P在疥疮皮损的临床消退方面同样有效。与基线相比,P在第2周时将CG和IS分别从3.4±0.7和3.1±0.4降至0.2±0.6和1.4±1,在第4周时分别降至0.0±0.0和0.1±0.3(P<0.001)。F在第2周时将CG和IS分别从3.3±0.5和3.2±0.4降至0.05±0.2和0.4±0.6,在第4周时分别降至0.0±0.0和0.0±0.0(P<0.0001)。与P组相比,F组在第2周时的IS显著更低(0.4±0.6对1.4±1.1)(P<0.0013)。这种泡沫制剂在治疗疥疮方面至少与5%氯菊酯乳膏一样有效。与氯菊酯相比,这种泡沫能更快、更完全地缓解瘙痒。